Supernus Pharmaceuticals | SUPN - Gross Profit On Sales

Supernus Pharmaceuticals reported $144.37M in Gross Profit on Sales for its fourth fiscal quarter of 2022.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

API Features Documentation Interested? Click here to contact us
Please Paste this Code in your Website
width
height
 Preview
Gross Profit On Sales Change
Abbott ABT:US USD 5.5B 283M
Ani Pharmaceuticals ANIP:US USD 57.91M 6.98M
Aurora Cannabis Inc ACB:CN CAD -22470000 354K
Bristol Myers Squibb BMY:US USD 8.89B 21M
Canopy Growth Corp WEED:CN CAD -2441000 6.26M
Cara Therapeutics CARA:US USD 1.13M 6.63M
Corcept Therapeutics CORT:US USD 101.58M 1.19M
Eisai 4523:JP JPY 140.84B 11.6B
Eli Lilly And LLY:US USD 5.75B 391.2M
Endo International Ordinary Shares ENDP:US USD 364.83M 28.49M
Horizon Pharma HZNP:US USD 701.24M 10.01M
JAZZ PHA JAZZ:US USD 804.76M 2.23M
Marinus Pharmaceuticals MRNS:US USD 6.87M 4.58M
Pacira Pharmaceuticals PCRX:US USD 110.04M 6.75M
Perrigo Ordinary Shares PRGO:US USD 382.6M 19.7M
Pfizer PFE:US USD 14.47B 2.08B
Revance Therapeutics RVNC:US USD 26.41M 8.13M
Supernus Pharmaceuticals SUPN:US USD 144.37M 7.1M
Teva Pharmaceutical Industries TEVA:US USD 2.1B 390M
United Therapeutics UTHR:US USD 432.7M 46.1M
Xeris Pharmaceuticals Inc XERS:US USD 26.85M 2.39M